|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/16 Mannkind Corp 10-K 12/31/15 91:10M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.10M
2: EX-4.17 Instrument Defining the Rights of Security Holders HTML 74K
4: EX-10.36 Material Contract HTML 97K
5: EX-10.37 Material Contract HTML 24K
6: EX-10.38 Material Contract HTML 34K
3: EX-10.8 Material Contract HTML 54K
7: EX-23.1 Consent of Experts or Counsel HTML 25K
8: EX-31 Certification -- §302 - SOA'02 HTML 29K
9: EX-32 Certification -- §906 - SOA'02 HTML 26K
16: R1 Document and Entity Information HTML 55K
17: R2 Consolidated Balance Sheets HTML 113K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
19: R4 Consolidated Statements of Operations HTML 72K
20: R5 Consolidated Statements of Comprehensive Loss HTML 41K
21: R6 Consolidated Statements of Stockholders' (Deficit) HTML 140K
22: R7 Consolidated Statements of Cash Flows HTML 160K
23: R8 Description of business and basis of presentation HTML 39K
24: R9 Summary of significant accounting policies HTML 73K
25: R10 State research and development credit exchange HTML 27K
receivable
26: R11 Inventories HTML 34K
27: R12 Property and equipment HTML 51K
28: R13 Accrued expenses and other current liabilities HTML 32K
29: R14 Related-party arrangements HTML 36K
30: R15 Senior convertible notes HTML 51K
31: R16 Collaboration arrangement HTML 49K
32: R17 Fair Value of Financial Instruments HTML 50K
33: R18 Common and preferred stock HTML 33K
34: R19 Net loss per common share HTML 38K
35: R20 Stock award plans HTML 86K
36: R21 Commitments and contingencies HTML 40K
37: R22 Employee benefit plans HTML 28K
38: R23 Income taxes HTML 77K
39: R24 Facility Agreement HTML 41K
40: R25 Restructuring Charges HTML 30K
41: R26 Selected quarterly financial data (Unaudited) HTML 47K
42: R27 Subsequent Events HTML 31K
43: R28 Description of business and basis of presentation HTML 154K
(Policies)
44: R29 Inventories (Tables) HTML 33K
45: R30 Property and equipment (Tables) HTML 43K
46: R31 Accrued expenses and other current liabilities HTML 32K
(Tables)
47: R32 Senior convertible notes (Tables) HTML 39K
48: R33 Fair Value of Financial Instruments (Tables) HTML 35K
49: R34 Net loss per common share (Tables) HTML 35K
50: R35 Stock award plans (Tables) HTML 83K
51: R36 Income taxes (Tables) HTML 74K
52: R37 Facility Agreement (Tables) HTML 29K
53: R38 Selected quarterly financial data (Unaudited) HTML 45K
(Tables)
54: R39 Description of Business and Basis of Presentation HTML 63K
- Additional Information (Detail)
55: R40 Summary Of Significant Accounting Policies - HTML 70K
Additional Information (Detail)
56: R41 State Research and Development Credit Exchange HTML 29K
Receivable - Additional Information (Detail)
57: R42 Components of Inventories (Detail) HTML 38K
58: R43 Property and Equipment (Detail) HTML 71K
59: R44 Property and Equipment - Additional Information HTML 44K
(Detail)
60: R45 Accrued Expenses and Other Current Liabilities HTML 40K
(Detail)
61: R46 Related-Party Arrangements - Additional HTML 85K
Information (Detail)
62: R47 Summary of Senior Convertible Notes (Detail) HTML 41K
63: R48 Senior Convertible Notes - Additional Information HTML 106K
(Detail)
64: R49 Collaborative Arrangement - Additional Information HTML 93K
(Detail)
65: R50 Fair Value of Financial Instruments - Additional HTML 108K
Information (Detail)
66: R51 Summary of Carrying Values Estimated Fair Values HTML 43K
of Notes and Facility Financing Obligation and
Sanofi Loan Facility (Detail)
67: R52 Common and Preferred Stock - Additional HTML 113K
Information (Detail)
68: R53 Net Loss per Common Share - Additional Information HTML 30K
(Detail)
69: R54 Potentially Dilutive Securities Outstanding HTML 40K
(Detail)
70: R55 Stock Award Plans - Additional Information HTML 112K
(Detail)
71: R56 Stock Based Award Plans (Detail) HTML 42K
72: R57 Stock Based Compensation Expense Recognized in HTML 34K
Accompanying Statements of Operation (Detail)
73: R58 Stock Based Compensation Expense Recognized in HTML 34K
Accompanying Statements of Operations by Category
(Detail)
74: R59 Fair Value of Employee Stock Options Assumptions HTML 45K
(Detail)
75: R60 Summary of Stock Options Outstanding (Detail) HTML 71K
76: R61 Summary of Restricted Stock Unit Activity (Detail) HTML 49K
77: R62 Commitments and Contingencies - Additional HTML 53K
Information (Detail)
78: R63 Employee Benefit Plans - Additional Information HTML 28K
(Detail)
79: R64 Provision for Income Taxes (Detail) HTML 60K
80: R65 Components of Net Deferred Tax Asset (Detail) HTML 60K
81: R66 Income Taxes -Additional Information (Detail) HTML 52K
82: R67 Effective Income Tax Rate (Detail) HTML 43K
83: R68 Facility Agreement - Additional Information HTML 98K
(Detail)
84: R69 Accretion of Debt Issuance Cost and Debt Discount HTML 33K
in Connection with Deerfield Financing (Detail)
85: R70 Restructuring Charges - Additional Information HTML 44K
(Detail)
86: R71 Selected Quarterly Financial Data (Detail) HTML 38K
87: R72 Selected Quarterly Financial Data - Additional HTML 28K
Information (Detail)
88: R73 Subsequent Events - Additional Information HTML 39K
(Detail)
90: XML IDEA XML File -- Filing Summary XML 159K
89: EXCEL IDEA Workbook of Financial Reports XLSX 104K
10: EX-101.INS XBRL Instance -- mnkd-20151231 XML 1.51M
12: EX-101.CAL XBRL Calculations -- mnkd-20151231_cal XML 230K
13: EX-101.DEF XBRL Definitions -- mnkd-20151231_def XML 1.32M
14: EX-101.LAB XBRL Labels -- mnkd-20151231_lab XML 1.68M
15: EX-101.PRE XBRL Presentations -- mnkd-20151231_pre XML 1.47M
11: EX-101.SCH XBRL Schema -- mnkd-20151231 XSD 234K
91: ZIP XBRL Zipped Folder -- 0001193125-16-505366-xbrl Zip 225K
| EX-10.38 |
Exhibit 10.38
|
25134 Rye Canyon Loop Suite 300 Main: (661) 775-5300 |
Michael Castagna
638 Lindero Canyon Road, Suite 333
Dear Michael,
Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position Chief Commercialization Officer located in Valencia CA. In this position you will initially report directly to Matthew J. Pfeffer, Chief Executive Officer and CFO.
We will target your employment to commence on March 14, 2016. Please be advised that this offer is contingent upon satisfactory reference and background checks and receipt of results of a satisfactory drug screening test. In the coming days, you will receive an email with information regarding the test, contact and location information for the laboratory as well as the hours of operation. This screening test must be completed no later than two weeks from the date of this letter.
You will be paid on a bi-weekly basis, on regular payroll schedule, in the amount of $15,384.61, equating to an annualized amount of $400,000.00. You will be eligible to participate in the MannKind Discretionary Bonus Plan, with a target bonus opportunity of 50% of annual earnings. You will be eligible for a car allowance of $553.85 paid on a biweekly basis equating to an annualized amount of $14,400.00.
Additionally, you will receive a one-time sign-on bonus in the gross amount of $50,000.00, less appropriate with-holdings and other payroll deductions, payable as a lump sum on the first pay period at the end of the first ninety (90) days of your employment. By accepting this offer, you agree that, in the event that you voluntarily leave the Company, or if you are terminated by the Company for “cause”, within the twelve (12) months following receipt of payment, you will repay the full amount of the payment, net any with-holdings within thirty (30) days after the last day of your employment. By accepting this offer, you further agree that the Company may deduct this amount from any other amounts The Company owes you should you be obligated to repay this amount.
You will be eligible to participate in MannKind’s Equity Incentive Plan, under which stock options and restricted stock will be awarded to you at a future date, as approved by the Board of Directors. At the next quarterly Board meeting after your hire date, we will recommend that you be granted an equity award of 329,200 stock options and 80,000 restricted stock units which is comparable to grants made for other individuals in similar level positions throughout the company. This is not a guarantee for a specific
Michael Castagna, page two
number of restricted stock units, but is only intended to provide you with an understanding of grant guidelines for your position. If your start date is less than two weeks prior to the next quarterly Board meeting, the recommendation will be submitted in the following quarter. Grants will begin vesting based on your hire date. You will also be eligible for an annual equity grant.
Additionally, the Board will be asked to make a special grant of 1,000,000 performance based stock options, with performance based vesting terms to be mutually agreed upon in advance of their grant date.
We have a substantial list of fringe benefits, including the following: 22 days PTO annually, which accrues on a bi-weekly basis; short term and long term disability insurance; company–paid life insurance; a 401(k) tax deferred savings program; flexible spending accounts; health, vision and dental insurance, and twelve paid holidays. The holidays and other time off benefits will be prorated based on your date of hire. All benefits, policies and rules are subject to change from time to time at the Company’s discretion. All benefits outlined in this offer letter are contingent on your continuing employment with MannKind Corporation in a benefit eligible status.
Shortly after we are in receipt of your acceptance, you will receive a welcome email from our onboarding manager, with a link to your personalized onboarding portal. Through this portal you will have access to most of the required MannKind policies and agreements that will require your signature such as, the Employee Proprietary Information and Inventions Agreement, an Arbitration Agreement, a Policy Against Insider Trading, Code of Business Conduct and Ethics, and an Employee Acknowledgement Form, required after reading the MannKind Employee Sourcebook. Of course, the company may require additional policies or agreements to be signed and acknowledged in the future.
Employment at MannKind is at will, which means that either you or MannKind can end the employment relationship at any time, and for any reason or for no reason, with or without cause or notice. The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether oral or written, and cannot be modified or amended except in writing by an officer of the company. As required by law, this offer is subject to satisfactory proof of your right to work in the United States. This at will employment relationship cannot be changed except in writing as approved by the Board of Directors of MannKind.
We appreciate the energy and enthusiasm you demonstrated during our interview and selection process and we look forward to a favorable response to our offer. We have many exciting challenges ahead and believe you can make a significant contribution to MannKind.
At your earliest convenience, please sign and date this letter and return it to Linda Adreveno, Sr. V. P. Human Resources (ladreveno@mannkindcorp.com) to indicate your acceptance of this written offer of employment. Please also include proof of your annual compensation in the form of a recent pay stub or W2/1099.
If you should have any questions, please don’t hesitate to contact me.
| Sincerely, |
| /s/ Matthew J. Pfeffer |
| Chief Executive Officer and CFO |
Michael Castagna, page three
I have carefully read and understand all of the terms of the above letter and freely and voluntarily accept and agree to all of its terms. I represent that, in agreeing to this offer letter, I am not relying on any representations or promises of any kind other than set forth in this letter.
| /s/ Michael Castagna |
| Michael Castagna |
| March 9, 2016 |
| Date Signed |
| March 14, 2016 |
| Confirmed Start Date |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/15/16 | |||
| 3/14/16 | 8-K | |||
| 3/9/16 | ||||
| 3/3/16 | ||||
| For Period end: | 12/31/15 | NT 10-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/24 Mannkind Corp. 10-K 12/31/23 123:18M Donnelley … Solutions/FA 2/23/23 Mannkind Corp. 10-K 12/31/22 135:24M ActiveDisclosure/FA 2/24/22 Mannkind Corp. 10-K 12/31/21 108:17M ActiveDisclosure/FA 2/25/21 Mannkind Corp. 10-K 12/31/20 107:15M ActiveDisclosure/FA 11/04/20 Mannkind Corp. 10-Q 9/30/20 83:13M ActiveDisclosure/FA 8/05/20 Mannkind Corp. 10-Q 6/30/20 82:12M ActiveDisclosure/FA |